$ANTH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Anthera Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Anthera Pharmaceuticals Inc. Get notifications about new insider transactions in Anthera Pharmaceuticals Inc for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 25 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 8.18 | 24,193 | 197,899 | 4,922,134 | 4.9 M to 4.9 M (-0.49 %) |
| May 19 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 8.03 | 412 | 3,308 | 18,012 | 18.4 K to 18 K (-2.24 %) |
| May 19 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 8.03 | 11,337 | 91,036 | 495,175 | 506.5 K to 495.2 K (-2.24 %) |
| May 19 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 8.03 | 113,251 | 909,406 | 4,946,327 | 5.1 M to 4.9 M (-2.24 %) |
| May 19 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 8.29 | 46 | 381 | 18,424 | 18.5 K to 18.4 K (-0.25 %) |
| May 19 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 8.29 | 1,261 | 10,454 | 506,512 | 507.8 K to 506.5 K (-0.25 %) |
| May 19 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 8.29 | 12,593 | 104,396 | 5,059,578 | 5.1 M to 5.1 M (-0.25 %) |
| May 18 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Sell | S | 7.16 | 15,000 | 107,339 | 692,003 | 707 K to 692 K (-2.12 %) |
| May 18 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Gift | G | 0.00 | 9,000 | 0 | 707,003 | 716 K to 707 K (-1.26 %) |
| May 18 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Gift | G | 0.00 | 30,000 | 0 | 716,003 | 686 K to 716 K (+4.37 %) |
| May 18 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Gift | G | 0.00 | 30,000 | 0 | 91,122 | 121.1 K to 91.1 K (-24.77 %) |
| May 18 2011 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 8.03 | 69,334 | 556,752 | 3,139,000 | 3.2 M to 3.1 M (-2.16 %) |
| May 18 2011 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 8.32 | 100,000 | 832,000 | 3,208,334 | 3.3 M to 3.2 M (-3.02 %) |
| May 18 2011 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 7.20 | 12,000 | 86,400 | 3,308,334 | 3.3 M to 3.3 M (-0.36 %) |
| May 11 2011 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 7.22 | 13,000 | 93,860 | 3,320,334 | 3.3 M to 3.3 M (-0.39 %) |
| May 11 2011 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 7.23 | 106,400 | 769,272 | 3,333,334 | 3.4 M to 3.3 M (-3.09 %) |
| May 11 2011 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 7.26 | 10,000 | 72,600 | 3,439,734 | 3.4 M to 3.4 M (-0.29 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.01 | 1,279 | 8,966 | 18,470 | 19.7 K to 18.5 K (-6.48 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.01 | 35,164 | 246,500 | 507,774 | 542.9 K to 507.8 K (-6.48 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.01 | 351,257 | 2,462,312 | 5,072,171 | 5.4 M to 5.1 M (-6.48 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.00 | 660 | 4,620 | 19,749 | 20.4 K to 19.7 K (-3.23 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.00 | 18,140 | 126,980 | 542,938 | 561.1 K to 542.9 K (-3.23 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.00 | 181,200 | 1,268,400 | 5,423,428 | 5.6 M to 5.4 M (-3.23 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.00 | 330 | 2,310 | 20,409 | 20.7 K to 20.4 K (-1.59 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.00 | 9,070 | 63,490 | 561,078 | 570.1 K to 561.1 K (-1.59 %) |
| May 05 2011 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Sell | S | 7.00 | 90,600 | 634,200 | 5,604,628 | 5.7 M to 5.6 M (-1.59 %) |
| Apr 14 2011 | ANTH | Anthera Pharmaceut ... | ODINK DEBRA | VP, Pharmaceutical ... | Option Exercise | M | 1.51 | 3,311 | 5,000 | 25,894 | |
| Apr 14 2011 | ANTH | Anthera Pharmaceut ... | ODINK DEBRA | VP, Pharmaceutical ... | Buy | M | 1.51 | 3,311 | 5,000 | 29,311 | 26 K to 29.3 K (+12.73 %) |
| Apr 14 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Option Exercise | M | 0.26 | 30,000 | 7,800 | 332,826 | |
| Apr 14 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Buy | M | 0.26 | 30,000 | 7,800 | 121,122 | 91.1 K to 121.1 K (+32.92 %) |
| Apr 14 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Gift | G | 0.00 | 7,250 | 0 | 686,003 | 693.3 K to 686 K (-1.05 %) |
| Apr 14 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Gift | G | 0.00 | 693,253 | 0 | 693,253 | 0 to 693.3 K |
| Apr 14 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Gift | G | 0.00 | 693,253 | 0 | 91,122 | 784.4 K to 91.1 K (-88.38 %) |
| Feb 14 2011 | ANTH | Anthera Pharmaceut ... | Hislop Colin | Chief Medical Offic ... | Buy | P | 0.00 | 3,894 | 0 | 50,062 | 46.2 K to 50.1 K (+8.43 %) |
| Jan 05 2011 | ANTH | Anthera Pharmaceut ... | Thompson David E. | Director | Option Exercise | M | 1.51 | 3,407 | 5,145 | 2,434 | |
| Jan 05 2011 | ANTH | Anthera Pharmaceut ... | Thompson David E. | Director | Option Exercise | M | 1.34 | 8,151 | 10,922 | 3,531 | |
| Jan 05 2011 | ANTH | Anthera Pharmaceut ... | Thompson David E. | Director | Buy | M | 1.51 | 3,407 | 5,145 | 11,558 | 8.2 K to 11.6 K (+41.80 %) |
| Jan 05 2011 | ANTH | Anthera Pharmaceut ... | Thompson David E. | Director | Buy | M | 1.34 | 8,151 | 10,922 | 8,151 | 0 to 8.2 K |
| Feb 14 2011 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | VP of Administratio ... | Sell | S | 0.00 | 80,997 | 0 | 0 | 81 K to 0 (-100.00 %) |
| Jan 04 2011 | ANTH | Anthera Pharmaceut ... | Hislop Colin | Sr. VP, Cardiovasc. ... | Option Exercise | A | 4.88 | 170,000 | 829,600 | 170,000 | |
| Jan 04 2011 | ANTH | Anthera Pharmaceut ... | ODINK DEBRA | VP, Pharmaceutical ... | Option Exercise | A | 4.88 | 95,000 | 463,600 | 95,000 | |
| Jan 04 2011 | ANTH | Anthera Pharmaceut ... | KILFOIL GEORGINA | SVP, Prod. Dev. & P ... | Option Exercise | A | 4.88 | 100,000 | 488,000 | 100,000 | |
| Jan 04 2011 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Option Exercise | A | 4.88 | 160,000 | 780,800 | 160,000 | |
| Jan 04 2011 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Option Exercise | A | 4.88 | 260,000 | 1,268,800 | 260,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | Thompson David E. | Director | Option Exercise | A | 4.19 | 12,000 | 50,280 | 12,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 4.19 | 12,000 | 50,280 | 12,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 4.19 | 12,000 | 50,280 | 12,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | Santel Donald J | Director | Option Exercise | A | 4.19 | 12,000 | 50,280 | 12,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 4.19 | 15,000 | 62,850 | 15,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Option Exercise | A | 4.19 | 12,000 | 50,280 | 12,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Option Exercise | A | 4.19 | 12,000 | 50,280 | 12,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | A | 4.19 | 12,000 | 50,280 | 12,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | Bianchi Annette | Director | Option Exercise | A | 4.19 | 12,000 | 50,280 | 12,000 | |
| Oct 04 2010 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 4.08 | 19,900 | 81,192 | 3,449,734 | 3.4 M to 3.4 M (+0.58 %) |
| Sep 24 2010 | ANTH | Anthera Pharmaceut ... | ODINK DEBRA | VP, Pharmaceutical ... | Buy | P | 4.20 | 1,000 | 4,200 | 26,000 | 25 K to 26 K (+4.00 %) |
| Sep 24 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Buy | P | 4.18 | 5,000 | 20,900 | 62,523 | 57.5 K to 62.5 K (+8.69 %) |
| Sep 24 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Option Exercise | P | 3.30 | 100,000 | 330,000 | 100,000 | |
| Sep 24 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Buy | P | 3.00 | 250,000 | 750,000 | 1,423,896 | 1.2 M to 1.4 M (+21.30 %) |
| Sep 23 2010 | ANTH | Anthera Pharmaceut ... | Trias Joaquim | Sr. VP, Preclinical ... | Option Exercise | M | 1.51 | 4,380 | 6,614 | 0 | |
| Sep 23 2010 | ANTH | Anthera Pharmaceut ... | Trias Joaquim | Sr. VP, Preclinical ... | Buy | M | 1.51 | 4,380 | 6,614 | 198,546 | 194.2 K to 198.5 K (+2.26 %) |
| Sep 23 2010 | ANTH | Anthera Pharmaceut ... | Hislop Colin | Sr. VP, Cardiovasc. ... | Option Exercise | M | 0.26 | 14,683 | 3,818 | 130,447 | |
| Sep 23 2010 | ANTH | Anthera Pharmaceut ... | Hislop Colin | Sr. VP, Cardiovasc. ... | Buy | M | 0.26 | 14,683 | 3,818 | 15,183 | 500 to 15.2 K (+2,936.60 %) |
| Aug 20 2010 | ANTH | Anthera Pharmaceut ... | Hislop Colin | Sr. VP, Cardiovasc. ... | Buy | P | 4.80 | 300 | 1,440 | 500 | 200 to 500 (+150.00 %) |
| Aug 20 2010 | ANTH | Anthera Pharmaceut ... | Hislop Colin | Sr. VP, Cardiovasc. ... | Buy | P | 4.80 | 200 | 960 | 200 | 0 to 200 |
| Jul 14 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Gift | G | 0.00 | 23,364 | 0 | 779,253 | 802.6 K to 779.3 K (-2.91 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Grant | A | 0.00 | 50,000 | 0 | 802,617 | 752.6 K to 802.6 K (+6.64 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Grant | A | 0.00 | 36,000 | 0 | 752,617 | 716.6 K to 752.6 K (+5.02 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | Trias Joaquim | Sr. VP, Preclinical ... | Grant | A | 0.00 | 15,000 | 0 | 194,166 | 179.2 K to 194.2 K (+8.37 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | Trias Joaquim | Sr. VP, Preclinical ... | Grant | A | 0.00 | 5,000 | 0 | 179,166 | 174.2 K to 179.2 K (+2.87 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | ODINK DEBRA | VP, Pharmaceutical ... | Grant | A | 0.00 | 20,000 | 0 | 25,000 | 5 K to 25 K (+400.00 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | ODINK DEBRA | VP, Pharmaceutical ... | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Grant | A | 0.00 | 22,000 | 0 | 57,523 | 35.5 K to 57.5 K (+61.93 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Grant | A | 0.00 | 18,000 | 0 | 35,523 | 17.5 K to 35.5 K (+102.72 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | Lau Stephen | VP, Corp. & Busines ... | Grant | A | 0.00 | 6,000 | 0 | 7,000 | 1,000 to 7 K (+600.00 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | Lau Stephen | VP, Corp. & Busines ... | Grant | A | 0.00 | 1,000 | 0 | 1,000 | 0 to 1,000 |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | KILFOIL GEORGINA | SVP, Prod. Dev. & P ... | Grant | A | 0.00 | 22,500 | 0 | 22,500 | 0 to 22.5 K |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | Hislop Colin | Sr. VP, Cardiovasc. ... | Grant | A | 0.00 | 30,000 | 0 | 45,841 | 15.8 K to 45.8 K (+189.38 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | Hislop Colin | Sr. VP, Cardiovasc. ... | Grant | A | 0.00 | 10,000 | 0 | 15,841 | 5.8 K to 15.8 K (+171.20 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | Fritsch Ursula | VP, Glob. Reg. & Co ... | Grant | A | 0.00 | 7,500 | 0 | 83,615 | 76.1 K to 83.6 K (+9.85 %) |
| Jul 02 2010 | ANTH | Anthera Pharmaceut ... | Fritsch Ursula | VP, Glob. Reg. & Co ... | Grant | A | 0.00 | 3,000 | 0 | 76,115 | 73.1 K to 76.1 K (+4.10 %) |
| Apr 07 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Option Exercise | M | 0.14 | 23,364 | 3,271 | 0 | |
| Apr 07 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Buy | M | 0.14 | 23,364 | 3,271 | 716,617 | 693.3 K to 716.6 K (+3.37 %) |
| Apr 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Option Exercise | M | 1.51 | 5,841 | 8,820 | 0 | |
| Apr 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Option Exercise | M | 1.34 | 29,205 | 39,135 | 0 | |
| Apr 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Option Exercise | M | 0.26 | 5,841 | 1,519 | 0 | |
| Apr 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Buy | M | 1.51 | 5,841 | 8,820 | 102,429 | 96.6 K to 102.4 K (+6.05 %) |
| Apr 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Buy | M | 1.34 | 29,205 | 39,135 | 96,588 | 67.4 K to 96.6 K (+43.34 %) |
| Apr 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Buy | M | 0.26 | 5,841 | 1,519 | 67,383 | 61.5 K to 67.4 K (+9.49 %) |
| Apr 02 2010 | ANTH | Anthera Pharmaceut ... | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 6.99 | 25,000 | 174,750 | 25,000 | |
| Apr 01 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Option Exercise | M | 0.14 | 2,920 | 409 | 0 | |
| Apr 01 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Option Exercise | M | 0.26 | 6,717 | 1,746 | 0 | |
| Apr 01 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Buy | M | 0.14 | 2,920 | 409 | 9,637 | 6.7 K to 9.6 K (+43.47 %) |
| Apr 01 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Buy | M | 0.26 | 6,717 | 1,746 | 6,717 | 0 to 6.7 K |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Option Exercise | A | 7.00 | 63,251 | 442,757 | 63,251 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Option Exercise | A | 7.00 | 42,167 | 295,169 | 42,167 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Option Exercise | C | 0.00 | 864,855 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Option Exercise | C | 0.00 | 828,323 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Option Exercise | C | 0.00 | 384,175 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Grant | A | 7.00 | 5,727 | 40,089 | 4,072,203 | 4.1 M to 4.1 M (+0.14 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Grant | A | 7.00 | 83,246 | 582,722 | 4,066,476 | 4 M to 4.1 M (+2.09 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Grant | A | 7.00 | 420,166 | 2,941,162 | 3,983,230 | 3.6 M to 4 M (+11.79 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Grant | A | 6.58 | 744,496 | 4,898,784 | 3,563,064 | 2.8 M to 3.6 M (+26.41 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Buy | C | 6.58 | 155,127 | 1,020,736 | 2,818,568 | 2.7 M to 2.8 M (+5.82 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Buy | C | 5.25 | 350,056 | 1,837,794 | 2,663,441 | 2.3 M to 2.7 M (+15.13 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Buy | C | 5.25 | 236,032 | 1,239,168 | 2,313,385 | 2.1 M to 2.3 M (+11.36 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Buy | C | 0.00 | 864,855 | 0 | 2,077,353 | 1.2 M to 2.1 M (+71.33 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Buy | C | 0.00 | 828,323 | 0 | 1,212,498 | 384.2 K to 1.2 M (+215.61 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | Sofinnova Management VI, L.L.C ... | 10% Owner | Buy | C | 0.00 | 384,175 | 0 | 384,175 | 0 to 384.2 K |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Option Exercise | A | 7.00 | 63,251 | 442,757 | 63,251 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Option Exercise | A | 7.00 | 42,167 | 295,169 | 42,167 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Option Exercise | C | 0.00 | 864,855 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Option Exercise | C | 0.00 | 828,323 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Option Exercise | C | 0.00 | 384,175 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Grant | A | 7.00 | 420,166 | 2,941,162 | 3,983,230 | 3.6 M to 4 M (+11.79 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Grant | A | 6.58 | 744,496 | 4,898,784 | 3,563,064 | 2.8 M to 3.6 M (+26.41 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | C | 6.58 | 155,127 | 1,020,736 | 2,818,568 | 2.7 M to 2.8 M (+5.82 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | C | 5.25 | 350,056 | 1,837,794 | 2,663,441 | 2.3 M to 2.7 M (+15.13 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | C | 5.25 | 236,032 | 1,239,168 | 2,313,385 | 2.1 M to 2.3 M (+11.36 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | C | 0.00 | 864,855 | 0 | 2,077,353 | 1.2 M to 2.1 M (+71.33 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | C | 0.00 | 828,323 | 0 | 1,212,498 | 384.2 K to 1.2 M (+215.61 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | SOFINNOVA VENTURE PARTNERS VI ... | 10% Owner | Buy | C | 0.00 | 384,175 | 0 | 384,175 | 0 to 384.2 K |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Option Exercise | A | 7.00 | 63,251 | 442,757 | 63,251 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Option Exercise | A | 7.00 | 42,167 | 295,169 | 42,167 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Option Exercise | C | 0.00 | 864,855 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Option Exercise | C | 0.00 | 828,323 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Option Exercise | C | 0.00 | 384,175 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Grant | A | 7.00 | 5,727 | 40,089 | 4,092,646 | 4.1 M to 4.1 M (+0.14 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Grant | A | 7.00 | 83,246 | 582,722 | 4,086,919 | 4 M to 4.1 M (+2.08 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Grant | A | 7.00 | 420,166 | 2,941,162 | 4,003,673 | 3.6 M to 4 M (+11.72 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Grant | A | 6.58 | 744,496 | 4,898,784 | 3,583,507 | 2.8 M to 3.6 M (+26.22 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Buy | C | 6.58 | 155,127 | 1,020,736 | 2,839,011 | 2.7 M to 2.8 M (+5.78 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Buy | C | 5.25 | 350,056 | 1,837,794 | 2,683,884 | 2.3 M to 2.7 M (+15.00 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Buy | C | 5.25 | 236,032 | 1,239,168 | 2,333,828 | 2.1 M to 2.3 M (+11.25 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Buy | C | 0.00 | 864,855 | 0 | 2,097,796 | 1.2 M to 2.1 M (+70.15 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Buy | C | 0.00 | 828,323 | 0 | 1,232,941 | 404.6 K to 1.2 M (+204.72 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | HEALY JAMES | Director | Buy | C | 0.00 | 384,175 | 0 | 404,618 | 20.4 K to 404.6 K (+1,879.25 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Option Exercise | C | 0.00 | 8,567 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Option Exercise | C | 0.00 | 20,719 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Buy | C | 0.00 | 8,567 | 0 | 693,253 | 684.7 K to 693.3 K (+1.25 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Buy | C | 0.00 | 20,719 | 0 | 684,686 | 664 K to 684.7 K (+3.12 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 7.00 | 323 | 2,261 | 323 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 7.00 | 8,881 | 62,167 | 8,881 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 7.00 | 88,717 | 621,019 | 88,717 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 7.00 | 215 | 1,505 | 215 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 7.00 | 5,920 | 41,440 | 5,920 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 7.00 | 59,144 | 414,008 | 59,144 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 3,463 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 95,194 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 950,897 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 4,886 | 0 | 0 |